(Q37990401)

26 August 2017

title

Yttrium-labelled peptides for therapy of NET. (English)

1 reference

26 August 2017

1 reference

Lisa Bodei

1

1 reference

26 August 2017

Marta Cremonesi

2

1 reference

26 August 2017

Chiara M Grana

3

1 reference

26 August 2017

Marco Chinol

4

1 reference

26 August 2017

Silvia M Baio

5

1 reference

26 August 2017

Stefano Severi

6

1 reference

26 August 2017

Giovanni Paganelli

7

1 reference

26 August 2017

publication date

1 February 2012

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

26 August 2017

published in

1 reference

26 August 2017

volume

39 Suppl 1

1 reference

26 August 2017

page(s)

S93-102

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-011-2002-y

26 August 2017

exact match

0 references

cites work

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Peptide receptor therapies in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Clinical radiation nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

End-stage renal disease after treatment with 90Y-DOTATOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

90Y-edotreotide for metastatic carcinoid refractory to octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2002-Y

New advances in peptide receptor radionuclide therapy.

21 January 2018

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

12 December 2020

The radiobiology of conventional radiotherapy and its application to radionuclide therapy

1 reference

12 December 2020

Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

1 reference

12 December 2020

Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

1 reference

12 December 2020

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

12 December 2020

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

12 December 2020

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

12 December 2020

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake

1 reference

12 December 2020

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

1 reference

12 December 2020

Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid)

1 reference

12 December 2020

Evaluation of quantitative planar90Y bremsstrahlung whole-body imaging

1 reference

12 December 2020

10.1007/S00259-011-2002-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference